Search Clinical Trials
583,492 trials
ID
Status
Phase
Title
Sponsor
NCT07573631
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular DystrophyBioMarin PharmaceuticalEnrolling By InvitationPhase 2
NCT07573631Enrolling By Invitation
Phase 2
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of B...BioMarin Pharmaceutical
NCT07573150
Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing TonsillectomyNational Institute on Drug Abuse (NIDA)Not Yet Recruiting
NCT07573150Not Yet Recruiting
—
Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Dep...National Institute on Dru...
NCT07574320
Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel SyndromeMd. Aminul IslamNot Yet RecruitingPhase 4
NCT07574320Not Yet Recruiting
Phase 4
Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndr...Md. Aminul Islam
NCT07572929
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic TransplantMedical College of WisconsinNot Yet RecruitingPhase 2
NCT07572929Not Yet Recruiting
Phase 2
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Meas...Medical College of Wiscon...
NCT07572175
Sotagliflozin as Prevention of Anthracycline-Related CardiotoxicityAmerican Heart AssociationNot Yet RecruitingPhase 2
NCT07572175Not Yet Recruiting
Phase 2
Sotagliflozin as Prevention of Anthracycline-Related CardiotoxicityAmerican Heart Associatio...
NCT07572136
Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-cell Acute Lymphoblastic Leukemia (B-ALL)National Cancer Institute (NCI)Not Yet RecruitingPhase 1
NCT07572136Not Yet Recruiting
Phase 1
Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T...National Cancer Institute...
NCT07573189
The Effects of Recovery Compression Boots on Blood Lactate Levels, Functional Movement, and Joint Ange of Motion in Collegiate Athletes.University of RedlandsActive Not RecruitingNot Applicable
NCT07573189Active Not Recruiting
Not Applicable
The Effects of Recovery Compression Boots on Blood Lactate Levels, Functional Mo...University of Redlands
NCT07572747
Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf CountriesKhalid F AlhabibNot Yet RecruitingPhase 3
NCT07572747Not Yet Recruiting
Phase 3
Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf Countrie...Khalid F Alhabib
NCT07573371
Understanding and Tailored Treatment of Low Anterior Resection SyndromeAalborg University HospitalRecruiting
NCT07573371Recruiting
—
Understanding and Tailored Treatment of Low Anterior Resection SyndromeAalborg University Hospit...
NCT07574333
Effects of Short and Long Courses of Intermittent Hypoxic-Hyperoxic Training in Patients With Type 2 Diabetes Including ElderlyNational Medical Research Center for Therapy and Preventive MedicineRecruitingNot Applicable
NCT07574333Recruiting
Not Applicable
Effects of Short and Long Courses of Intermittent Hypoxic-Hyperoxic Training in...National Medical Research...
NCT07573215
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaRevolution Medicines, Inc.Unknown
NCT07573215Unknown
—
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metast...Revolution Medicines, Inc...
NCT07572084
Romiplostim N01 in Chemoradiotherapy-induced Aplastic AnemiaPeking Union Medical College HospitalNot Yet RecruitingPhase 2
NCT07572084Not Yet Recruiting
Phase 2
Romiplostim N01 in Chemoradiotherapy-induced Aplastic AnemiaPeking Union Medical Coll...
NCT07573787
Homoeriodictyol Sodium Mouthwash to Reduce Chemotherapy Induced Bitter Taste DisordersChristoph GrimmTerminatedNot Applicable
NCT07573787Terminated
Not Applicable
Homoeriodictyol Sodium Mouthwash to Reduce Chemotherapy Induced Bitter Taste Dis...Christoph Grimm
NCT07574281
Effectiveness and Implementation of the DINKNESH Digital Palliative Care Tool in EthiopiaAddis Ababa UniversityNot Yet RecruitingNot Applicable
NCT07574281Not Yet Recruiting
Not Applicable
Effectiveness and Implementation of the DINKNESH Digital Palliative Care Tool in...Addis Ababa University
NCT07573748
Apple Vision Pro-Assisted Vascular Identification in Lung SurgeryThe Second People's Hospital of Huai'anNot Yet RecruitingNot Applicable
NCT07573748Not Yet Recruiting
Not Applicable
Apple Vision Pro-Assisted Vascular Identification in Lung SurgeryThe Second People's Hospi...
NCT07573059
Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated PatientsImmedica Pharma US IncRecruitingNot Applicable
NCT07573059Recruiting
Not Applicable
Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated Pati...Immedica Pharma US Inc
NCT07573046
Validation Study of the ExéSem Battery Designed to Differentiate the Contribution of Executive Functions in Semantic DisordersHospices Civils de LyonNot Yet Recruiting
NCT07573046Not Yet Recruiting
—
Validation Study of the ExéSem Battery Designed to Differentiate the Contributio...Hospices Civils de Lyon
NCT07573800
tDCS and the Cardiovascular System in Community-dwelling Elderly.Riphah International UniversityNot Yet RecruitingNot Applicable
NCT07573800Not Yet Recruiting
Not Applicable
tDCS and the Cardiovascular System in Community-dwelling Elderly.Riphah International Univ...
NCT07574047
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.Swiss Cancer InstituteNot Yet RecruitingPhase 4
NCT07574047Not Yet Recruiting
Phase 4
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for...Swiss Cancer Institute
Result Breakdown
Not yet recruiting12 (60%)
Recruiting3 (15%)
Enrolling by invitation1 (5%)
Completed1 (5%)
Active, not recruiting1 (5%)
Unknown1 (5%)
Terminated1 (5%)
not_applicable7 (35%)
Not Specified5 (25%)
Phase 24 (20%)
Phase 42 (10%)
Phase 11 (5%)
Phase 31 (5%)